Needham Maintains Buy on NewAmsterdam Pharma Co, Lowers Price Target to $46

Benzinga · 9h ago
Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and lowers the price target from $48 to $46.